Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ME Therapeutics HoldingFRA:Q9T 14 Receivables Turnover is 0.00 as of May. 2026. GuruFocus rates FRA:Q9T with a GF Score™ of 14/100. The stock has 1 warning sign investors should review. Among 847 Biotechnology companies, ME Therapeutics Holding ranks worse than 118063.64% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. ME Therapeutics Holding's Revenue for the
three
months ended in May. 2026 was €0.00 Mil. ME Therapeutics Holding's average Accounts Receivable for the
three
months ended in May. 2026 was €0.00 Mil.
ME Therapeutics Holding (FRA:Q9T) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
ME Therapeutics Holding Receivables Turnover Related Terms
ME Therapeutics Holding Receivables Turnover Historical Data
* Premium members only.
The historical data trend for ME Therapeutics Holding's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ME Therapeutics Holding Receivables Turnover Chart
FRA:Q9T vs VRTX, REGN, RVMD: Receivables Turnover Comparison
For the Biotechnology subindustry, ME Therapeutics Holding's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ME Therapeutics Holding Receivables Turnover vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ME Therapeutics Holding's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where ME Therapeutics Holding's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ME Therapeutics Holding (FRA:Q9T) has a Receivables Turnover of 0.00 as of May. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on ME Therapeutics Holding and its competitors. According to the industry distribution chart, ME Therapeutics Holding ranks #999999 out of 847 companies in the Biotechnology industry.
Is ME Therapeutics Holding's Receivables Turnover too high?
ME Therapeutics Holding's current Receivables Turnover is 0.00. Based on the distribution chart, ME Therapeutics Holding ranks #999999 out of 847 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, ME Therapeutics Holding has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does ME Therapeutics Holding's Receivables Turnover compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, ME Therapeutics Holding ranks #999999 out of 847 companies for Receivables Turnover. This places ME Therapeutics Holding in the lower half of its industry. The industry median Receivables Turnover is 5.28. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Biotechnology company?
The median Receivables Turnover among Biotechnology companies is 5.28, based on 847 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on ME Therapeutics Holding and its competitors. For the Biotechnology industry, the median Receivables Turnover is 5.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ME Therapeutics Holding's current Receivables Turnover is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ME Therapeutics Holding stock overvalued right now?
ME Therapeutics Holding (FRA:Q9T) has a current Receivables Turnover of 0.00. The current Receivables Turnover is 0.00. ME Therapeutics Holding's overall GF Score™ is 14/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For ME Therapeutics Holding (FRA:Q9T), the current Receivables Turnover is 0.00 as of May. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
ME Therapeutics Holding Inc is a preclinical stage biotechnology company working on cancer-fighting drugs in the field of Immuno Oncology, developing next-generation therapeutics targeting immune suppression in cancer. It is developing novel drugs that target myeloid cells to directly treat cancer and enhance the benefits of current Immuno Oncology drugs, such as checkpoint inhibitors in currently untreatable cancers. Immuno Oncology is a new area of cancer research that has been successful in treating previously untreatable cancers by targeting the immune system rather than the cancer directly, allowing a single drug to be used for multiple cancer types with mostly manageable side effects.
14GF Score
Get the complete analysis for FRA:Q9T
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:Q9T has been successfully added to your 
